CTIS2023-504116-14-00进行中（未招募）1 期
01TICA2023
Celon Pharma S.A.0 个研究点目标入组 40 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase I/II study assessing radioligand therapy (RLT) using 177Lu-PentixaTher for relapsed/refractory CXCR4+ acute leukemia.Acute LeukemiaCTIS2022-501019-15-00Centre Hospitalier Universitaire De Nantes21
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersdiabetes mellitushypertensionCTIS2024-511526-31-00Celon Pharma S.A.38
招募中
1 期
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple ascending oral doses to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of IAMA-6 and its interaction with foodCTIS2023-507454-33-00Iama Therapeutics S.r.l.72
进行中（未招募）
1 期
Incidence of postoperative residual neuromuscular blockade following the administration of rocuronium in thoracic surgical patients: a randomized placebo controlled studyAnesthesia and Analgesia, patient safetyCTIS2023-504745-31-00niversity Of Debrecen75
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55